Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001910004 | SCV002186070 | uncertain significance | Ataxia-telangiectasia syndrome | 2024-09-18 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 560 of the ATM protein (p.Glu560Gly). This variant is present in population databases (rs762476611, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 1408506). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Department of Clinical Genetics, |
RCV004809695 | SCV005431468 | uncertain significance | Familial cancer of breast; Ataxia-telangiectasia syndrome | 2024-12-04 | criteria provided, single submitter | clinical testing | The following ACMG criteria is used: PM2_Supporting (not reported in gnomAD); BP4 (Revel score 0.179) |
Center for Genomic Medicine, |
RCV005232713 | SCV005872592 | uncertain significance | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing |